About Us
The main objective of our company is to identify mRNA-based solutions to promote blood vessel formation in the body. For this we will use our selective modified mRNA platform to identify therapeutic gene combinations that allows new blood vessels to develop.
Our therapeutic approach could be beneficial to several disease and health conditions including ischemic heart disease, ischemic kidney disease, diabetes and hair loss.
The company is currently collaborating with Icahn School of Medicine at Mount Sinai, New York City to evaluate the potential therapeutic effect of our technology.
Lior Zangi Ph.D
Founder and Principal Investigator
Lior Zangi Ph.D is an Associate Professor of Cardiology and Associate Professor of Genetics and Genomic Sciences, with tenure, and he holds the Chan Soon-Shiong Professorship in Cardiovascular Research at the Icahn School of Medicine at Mount Sinai. His research focuses on methods for delivering modified mRNA (modRNA) to the heart to induce cardiac and cardiovascular regeneration and protection following ischemic injury.
His published work was the first to demonstrate modRNA delivery into cardiac and skeletal muscle and pioneered the use of modRNA to treat ischemic heart disease. His publications showed, for the first time, that modRNA technology can generate cardiac repair after heart attack and prevent heart failure formation, in both small and large animals.
Shilo Ben Zeev
Founder and CEO
A highly accomplished and driven entrepreneur with a proven track record in the medical device, consumer, and technology industries, Shilo Ben Zeev is renowned for his ability to identify unmet needs and create groundbreaking solutions that improve people's lives. As an entrepreneur with Type 1 diabetes, Shilo has placed quality of life, innovation, and user experience at the center of his mission. With twenty years of experience, he has raised over $100M, and founded, built, and scaled numerous companies including DarioHealth, a publicly traded diabetes management platform; Emendo Biotherapeutics, a gene editing company which was acquired for $350 million; and co-founder of Smartzyme Biopharma (protein engineering) and MyBiotics (gut health). His experience spans the establishment and management of startups from the initial stages including financing, business development and product development, through commercialization.
Currently he is founder and CEO of Emulait, the world's first baby bottle designed to mimic mom's breast in feel, form and function. Emulait is poised to disrupt the high-value billions of dollars millennial parenting market with its innovative technology and commitment to supporting families on their feeding journeys.